Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights [Yahoo! Finance]
Clene Inc. (CLNN)
Company Research
Source: Yahoo! Finance
Peer-reviewed publication characterized the protein corona of CNM-Au8 Company received sub-award of $7.3 million from NIH grant for ALS Expanded Access Program Cash, cash equivalents and marketable securities of $27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2024 financial results and provided recent operating highlights for the CNM-Au8 clinical program for MS. “In the first quarter our team worked diligently to advance our FDA discussions in ALS while continuing to generate more data supporting the neurological benefits and mechanism of action of CNM-Au8,” said Rob Etherington, President and C
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- NeuroSense taps PhaseV's ML tech for Phase III ALS trial analysis [Yahoo! Finance]Yahoo! Finance
- Clene to Present at Upcoming May Conferences [Yahoo! Finance]Yahoo! Finance
- Clene to Present at Upcoming May ConferencesGlobeNewswire
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Clene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsGlobeNewswire
CLNN
Earnings
- 5/8/24 - In-Line
CLNN
Sec Filings
- 5/8/24 - Form 4
- 5/8/24 - Form 8-K
- 5/8/24 - Form 10-Q
- CLNN's page on the SEC website